Insider Sale: Xeris (XERS) Director Disposes 42.5k Shares, Holds 115k

Rhea-AI Filing Summary

Dawn Halkuff, a director of Xeris Biopharma Holdings, Inc. (XERS), reported a sale of 42,500 shares executed on 08/12/2025 at a weighted average price of $7.2759. The filing states the shares were sold in multiple transactions at prices ranging from $7.190 to $7.450. After the reported dispositions, the filing shows 115,000 shares beneficially owned directly.

The report also discloses an indirect holding of 5,410 shares through the Dawn Halkuff Revocable Trust U/A DTD 08/25/2017 and states the reporting person disclaims beneficial ownership of those trust shares except to the extent of a pecuniary interest. No derivative securities are reported.

Positive

• Transparent price disclosure: the filing provides a weighted average sale price and the full reported execution price range
• No derivative transactions reported, keeping ownership changes straightforward

Negative

• Director disposition of 42,500 shares, reducing direct holdings to 115,000 shares
• Indirect trust holding of 5,410 shares is disclaimed, limiting clarity on beneficial control beyond pecuniary interest

Insights

Financial Analyst

TL;DR: Director sold 42,500 XERS shares at ~$7.28 each; direct holdings now 115,000 and 5,410 held indirectly in a trust.

The reported sale reduces the director's direct stake to 115,000 shares following multiple transactions at a weighted average price of $7.2759, with execution prices between $7.190 and $7.450. The filing includes clear price-range disclosure and a weighted-average price, which helps determine realized proceeds but does not by itself indicate intent or material company impact. No derivative activity is listed, limiting complexity of the ownership change. Without company-wide share counts or context, the transaction's market-significance cannot be assessed from this filing alone.

Corporate Governance Expert

TL;DR: Form 4 discloses an open-market sale by a director and an indirect trust holding; disclosure appears complete for the reported items.

The report documents a straightforward Section 16 disclosure: an open-market sale of 42,500 common shares and an indirect trust position of 5,410 shares. The inclusion of the weighted average price and the price range adds transparency. The filing also contains the reporting-person disclaimer regarding beneficial ownership of trust shares, which is a standard governance disclosure. There are no reported derivative transactions or other arrangements that would complicate the ownership picture.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HALKUFF DAWN

(Last) (First) (Middle)

C/O XERIS BIOPHARMA HOLDINGS, INC.

1375 WEST FULTON STREET, SUITE 1300

(Street)

CHICAGO IL 60607

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Xeris Biopharma Holdings, Inc. [ XERS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/12/2025		S		42,500	D	$7.2759(1)	115,000	D
Common Stock								5,410(2)	I	By; DAWN HALKUFF REVOCABLE TRUST U/A DTD 08/25/2017

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.190 to $7.450, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

2. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Remarks:

	/s/ Beth Hecht, Attorney-in-Fact	08/13/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Xeris (XERS) director Dawn Halkuff report on 08/12/2025?

The director reported the sale of 42,500 common shares executed on 08/12/2025 at a weighted average price of $7.2759.

How many XERS shares does Dawn Halkuff own after the reported transaction?

The filing shows 115,000 shares beneficially owned directly after the reported dispositions and an indirect trust holding of 5,410 shares.

At what prices were the XERS shares sold?

The shares were sold in multiple transactions at prices ranging from $7.190 to $7.450, with a weighted average of $7.2759.

Were any derivative securities reported for Dawn Halkuff on this Form 4?

No. Table II lists no derivative securities; only non-derivative common stock transactions are reported.

What indirect holdings are disclosed for Dawn Halkuff in the XERS filing?

The filing discloses 5,410 shares held indirectly by the Dawn Halkuff Revocable Trust U/A DTD 08/25/2017, with a disclaimer of beneficial ownership except for pecuniary interest.